6 Results for "

reversible slow-binding

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "reversible slow-binding" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-16693
CAS No.: 312946-37-5
Target:  

Glutaminase

Research Areas:  

Cardiovascular Disease Others

LDN-27219 is a reversible, slow-binding inhibitor of TGase. LDN-27219 inhibits human TGase with an IC50 value of 0.6 μM. LDN-27219 effectively decreases blood pressure and induces vasodilation, it can be used for the research of cardiovascular disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-124346
CAS No.: 1356354-09-0
Purity:  99.80%
Research Areas:  

Metabolic Disease

T-3364366 is a reversible, slow-binding, thienopyrimidinone delta-5 desaturase (D5D) inhibitor with IC50s of 1.9 nM and 2.1 nM in HepG2 and RLN-10 cells, respectively. T-3364366 exhibits potent D5D (IC500=19 nM) inhibitory activity and excellent selectivity away from delta-6 desaturase (D6D, IC50=6200 nM) and delta-9 desaturase (stearoyl-CoA desaturase, SCD,50 >10000 nM) in the enzymatic activity assay .
loading...
    loading...
Cat. No.: HY-134358A
Purity:  99.81%
Target:  

CD38

Research Areas:  

Neurological Disease

Ara-F-NAD+ sodium is an arabino analogue of NAD +. Ara-F-NAD+ sodium is a potent, reversible and slow-binding CD38 NADase inhibitor .
loading...
    loading...
Cat. No.: HY-134358
CAS No.: 133575-27-6
Target:  

CD38

Research Areas:  

Neurological Disease

Ara-F-NAD+ is an arabino analogue of NAD +. Ara-F-NAD+ is a potent, reversible and slow-binding CD38 NADase inhibitor .
loading...
    loading...
Cat. No.: HY-144812
CAS No.: 1043922-53-7
Target:  

Cathepsin

Research Areas:  

Inflammation/Immunology Cancer

Gü1303 is a potent, reversible, slow-binding cathepsin K (CatK) inhibitor with a Ki of 0.91 nM for mature CatK (mCatK). Gü1303 suppresses the autocatalytic activation of the cathepsin K zymogen .
loading...
    loading...
Cat. No.: HY-187382
Target:  

HDAC

Research Areas:  

Cancer

HDAC8-IN-17 is a histone deacetylase 8 inhibitor with human IC50 values of 0.08 μM, 0.44 μM, and 1.9 μM, and high selectivity over HDAC1, HDAC2, HDAC3, and HDAC6. HDAC8-IN-17 exhibits slow-binding, reversible uncompetitive inhibition via allosteric binding to the enzyme-substrate complex. HDAC8-IN-17 induces selective hyperacetylation of SMC3. HDAC8-IN-17 can be used for the research of cancer .
loading...
    loading...